阳光诺和：STC007注射液II期临床试验达成预期目标

Core Viewpoint - The clinical trial of STC007 injection for treating moderate to severe postoperative abdominal pain has met its expected goals, indicating potential for effective pain management in this area [1] Group 1: Clinical Trial Results - The Phase II clinical trial was conducted by Chengdu Nuoheshengtai Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, in collaboration with Huazhong University of Science and Technology [1] - A total of 156 subjects were involved in the trial across 20 research centers nationwide [1] - STC007 injection showed significant improvement in postoperative pain scores within 0-24 hours compared to the placebo group [1] - When compared to Tramadol hydrochloride injection, STC007 also demonstrated effective pain relief during movement for moderate to severe postoperative pain patients [1] Group 2: Safety and Tolerability - The overall safety and tolerability of STC007 injection were reported to be good [1] - No new safety signals were identified during the trial, and no serious adverse events occurred [1]